- Home
- OBE vs NMRA Comparison
OBE vs NMRA Comparison
Compare OBE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OBE | NMRA |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 554.0M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OBE | NMRA |
|---|---|---|
| Price | $12.92 | $1.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $10.00 | $7.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.61 | $0.66 |
| 52 Week High | $14.59 | $3.65 |
Technical Indicators
Market Signals| Indicator | OBE | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 34.94 |
| Support Level | $5.72 | $1.44 |
| Resistance Level | $14.59 | $1.90 |
| Average True Range (ATR) | 0.67 | 0.22 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 46.71 | 0.42 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.